The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments

6 organizations filed 6 public comments on The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments, at the Food and Drug Administration. The comment window closed 2615d ago.

Commenters (6)

• American Pharmacists Association (APhA)trade assoc.

  1 filing · confidence 97%
• American Society of Consultant Pharmaciststrade assoc.

  1 filing · confidence 85%
• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%
• Eli Lilly and Companyunverified attribution

  1 filing · confidence 70%
• Novartis Services Inc.unverified attribution

  1 filing · confidence 70%
• The Endocrine Societytrade assoc.

  1 filing · confidence 85%